Adult stem cell research continues apace. This PR press release touts an Australian company’s gaining FDA approval to conduct human experiments in treating heart disease with adult stem cells. It’s a “Phase 2 Trial,” meaning it tests efficacy as well as safety. From the release:
The Phase 2 clinical trial will be based at the Texas Heart Institute,and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission. These showed that implantation of the company’s proprietary allogeneic stem cells by catheter into damaged heart muscle resulted in significant improvement inheart function and reduction in congestive heart failure.Of course, most of the release is about the business aspect of all this. Life sciences: thy name is commerce.This clinical trial will be the first to test an allogeneic stem cell product injected by catheter into heart muscle damaged by a recent heart attack.
